DoH Policies screened during the period: 1 October 2017 – 31 December 2017
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- NICE Clinical Guideline NG72 - Developmental follow-up of children and young people born preterm
- NICE Clinical Guideline NG73 - Endometriosis: diagnosis and management
- NICE Clinical Guideline NG75 - Faltering growth: recognition and management of faltering growth in children
- NICE Technology Appraisal TA473 - Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (review of TA172)
- NICE Technology Appraisal TA474 - Sorafenib for treating advanced hepatocellular carcinoma (review of TA189)
- NICE Technology Appraisal TA475 - Dimethyl fumarate for treating moderate to severe plaque psoriasis
- NICE Technology Appraisal TA476 - Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (review of TA360)
- NICE Technology Appraisal TA477 - Autologous chondrocyte implantation for repairing symptomatic articular cartilage defects of the knee (review of TA89)
- NICE Technology Appraisal TA478 - Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
- NICE Technology Appraisal TA479 - Reslizumab for treating severe eosinophilic asthma
- NICE Technology Appraisal TA480 - Tofacitinib for moderate to severe rheumatoid arthritis
- NICE Technology Appraisal TA481 - Immunosuppressive therapy for kidney transplantation in adults (review of TA85)
- NICE Technology Appraisal TA482 - Immunosuppressive therapy for kidney transplant in children and young people (review of TA99)
- NICE Technology Appraisal TA485 - Sarilumab for moderate to severe rheumatoid arthritis
- NICE Technology Appraisal TA486 - Aflibercept for treating choroidal neovascularisation
- NICE Technology Appraisal TA488 - Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
- NICE Technology Appraisal TA489 - Vismodegib for treating basal cell carcinoma
- Regional HSC Whistleblowing Framework & Model Policy